Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

Now Viewing

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Lorlatinib’s Unique Adverse Event Profile

Key Themes:

• Cognitive effects, hypercholesterolemia, and peripheral neuropathy with lorlatinib
• Impact of adverse events on treatment selection
• Monitoring and management of cholesterol levels

Notable Insights:

• Dr Dietrich discussed lorlatinib’s unique adverse event profile and its impact on treatment decisions

Dr Lovly outlined best practices for monitoring and managing lorlatinib-induced hypercholesterolemia